Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed FCF Margin for 6 consecutive years, with 7500.7% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 198738.0% year-over-year to 7500.7%, compared with a TTM value of 4758.54% through Sep 2025, up 1162404.0%, and an annual FY2024 reading of 193.33%, up 683136.0% over the prior year.
  • FCF Margin was 7500.7% for Q3 2025 at Barinthus Biotherapeutics, up from 1814100.0% in the prior quarter.
  • Across five years, FCF Margin topped out at 839600.0% in Q4 2021 and bottomed at 1814100.0% in Q2 2025.
  • Average FCF Margin over 5 years is 48764.62%, with a median of 4303.12% recorded in 2021.
  • The sharpest move saw FCF Margin soared 84103814bps in 2021, then crashed -83969834bps in 2022.
  • Year by year, FCF Margin stood at 839600.0% in 2021, then crashed by -100bps to 98.34% in 2022, then skyrocketed by 282639bps to 277857.14% in 2023, then crashed by -97bps to 7965.12% in 2024, then tumbled by -194bps to 7500.7% in 2025.
  • Business Quant data shows FCF Margin for BRNS at 7500.7% in Q3 2025, 1814100.0% in Q2 2025, and 4717.41% in Q1 2025.